ND Partners, LLC

Privately held: no public share price

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Taurolidine/heparin(Defencath / Neutrolin)
Approved
Antimicrobial/antithrombotic catheter lock solutionSmall molecule
Chronic Kidney Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
January 2028 (1)
Taurolidine/heparin · Defencath / NeutrolinPhase 3Central Line Associated Blood Stream Infections (CLABSI)
Est. primary completion 2028-01 · NCT06822426 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.